What’s technology without insights? Data without context? Knowledge without action? We couldn’t do this without our partners and collaborators. Organisations who are as committed as we are to treating and preventing poor health. In our partnerships with Apple and Tencent we’re already doing vital work to improve lives the world over.
We’re working with 20 NHS Trusts including Royal Free, Guy's and St. Thomas', Chelsea & Westminster, and Royal Brompton across 30+ projects and 15 disease areas.
We have a research agreement with Johns Hopkins to collaborate on clinical validation for digital biomarker projects.
Bayer is leveraging Huma’s ecosystem, extensive hospital reach, and analytical capabilities to develop AI-driven digital and molecular cardiovascular therapies for those with Coronary Artery Disease (CAD). Together, we aim to create one of the most comprehensive prospective cardiovascular databases that will combine and analyse clinical, observational, biochemical, and genomic data with machine learning to develop biomarkers and digital therapeutics. The project begins in Hong Kong and will scale into additional geographies.
This is a joint project to support the care of patients undergoing Total Knee Arthroplasty (TKA). Phase one of the project will take place in the UK across five NHS sites and will use Huma’s modular technology to collect real-world data and deliver educational content to patients.
The long-term vision is to develop digital biomarkers that could quantify the effectiveness of medical devices and implants, and help Smith & Nephew’s Research & Development division develop innovative medical technology that delivers better outcomes for patients and healthcare systems.
Huma is working with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson to validate, scale and potentially commercialise the ReVeRe® platform as a novel digital biomarker for Alzheimer's disease (AD).
Huma and Swiss Re are exploring collaboration to deploy digital health insurance products for policyholders globally at scale. Utilising Huma’s full capabilities, the end product will provide chatbots for triage, digital biomarkers for screening and monitoring conditions, as well as disease management tools under a single user interface.
Huma is part of one of the consortiums led by the National University of Singapore (NUS) and National University Health System (NUHS) which won the AI in Health Grand Challenge from AI Singapore to help develop solutions for the three highs (3Hs): high cholesterol, high blood sugar, and hypertension.
Huma is a partner in the consortium led by Imperial College Health Partners (ICHP), creating a Health Data Research Hub for Real-World Evidence in the UK, alongside companies such as Google Health, AstraZeneca, and IBM.
Huma partnered with Boston Scientific to measure and improve outcomes for diseases such as Venous Leg Ulcers across the NHS and other healthcare providers. In this, we leveraged our ability to bring together third party solutions for tracking wounds. Our work combined smartphone cameras, Huma’s remote patient offering monitoring, and data aggregation and analysis capabilities.
Huma and Tencent have jointly established a medical AI lab. It’s made up of 50 team members working globally on AI projects to solve clinical problems. These include cancer, psoriasis, motion disorder syndromes like Parkinson’s disease, and the early detection of heart failure.
Huma and Medpod are collaborating to build a remote patient monitoring solution, enabling skilled nursing facilities and office-based physicians to monitor the vital signs of their cohort and make informed decisions about their health.
Huma and China Resources are jointly committed to scaling Huma’s remote patient monitoring solutions across hospitals in China with device partners. The teams are currently focusing on improving pathways for cardiac care with the aim to expand to other disease areas.
Medopad is now Huma. Huma has acquired Biobeats and TLT.